Sachdev Amit 4

What Happened

• Sachdev Amit, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (VRTX), was granted 8,251 restricted stock units (RSUs) on July 21, 2026. The award is reported at $0.00 per share (no cash purchase); total reported value $0.
• This transaction is an award/grant (Form 4 code A), not an open‑market purchase or sale. RSUs are compensation and typically convert to shares only after vesting.

Key Details

• Transaction date: 2026-07-21; filing date: 2026-07-23 (appears timely).
• Transaction type/code: Award/Grant (A).
• Shares granted: 8,251 RSUs at $0.00 (reported acquisition value $0).
• Vesting: Restricted stock unit award vests on 03/31/2030 (footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• No 10b5-1 plan, tax‑withholding info, or late filing flags were noted in the supplied data.

Context

• RSUs are a form of equity compensation that convert to actual shares only after vesting; they do not represent immediate market purchases or sales and are commonly granted to executives as part of pay packages.
• Because this is a grant rather than a buy or sell, it should be viewed as compensation-related, not a direct signal about the insider’s short‑term view of the stock price.